Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.

The UCL and Ludwig Institute-linked cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.

Repare Therapeutics, which is commericalising precision cancer drugs based on research at UofT and NYU, added $33m to its IPO after its shares rose 65% post-offering.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.

Cash Capital has celebrated an exit as UCloudlink raised $36.2m in its offering, after pricing its shares at the bottom of the range and issuing less stock than originally planned.

Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer, based on UCSF research, is set to raise up to $96m.

Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.